Aim Trials的封面图片
Aim Trials

Aim Trials

研究服务

Plano,Texas 290 位关注者

Reclaiming Better Health Through Clinical Research Studies

关于我们

Aim Trials is a local clinical research studies company conducting Mental Health and General Medicine trials for adults and children in the Dallas-Fort Worth area. Aim Trials is committed to conducting research studies with dedication, quality, efficiency and empathy. Our experienced doctors and clinical research team are proud to provide a high-quality of patient services, support for our sponsors, and a dedication to health and wellness for our participants. Aim Trials is a leading provider of mental health studies in the DFW area as well as providing other Phase I-IV research trials for adults and the pediatric population. We are a local company with a patient-centric approach to providing medical research that can help people across the globe. Aim Trials Research Company helping people We are dedicated to conducting clinical studies, investigating the effectiveness of new medicines and treatments in a variety of therapeutic areas. Our Theraputic Areas include: Internal medicine, allergy, asthma, immunology, cardiology, consumer studies, dermatology, neurology and headaches, obstetrics and gynecology, pediatrics, psychiatry (pediatric, adolescent and adult), oncology, vaccines and men’s and women’s health. In addition to traditional clinical trials, Aim Trials also specializes in human factor trials and user experience (UX) research trials. We focus on healthcare and decentralized research, utilizing cutting-edge technology platforms that enable remote sessions and hybrid models of in-person visits and telehealth. By incorporating these innovative approaches, we ensure convenience and accessibility for our participants while maintaining the highest standards of scientific rigor. As part of our commitment to advancing medical knowledge and exploring new avenues of treatment, Aim Trials is expanding into Psychedelic Studies.

网站
https://aimtrials.com/
所属行业
研究服务
规模
2-10 人
总部
Plano,Texas
类型
个体经营
创立
2019

地点

  • 主要

    6404 International Pkwy

    Suite 1010

    US,Texas,Plano,75093

    获取路线

Aim Trials员工

动态

  • 查看Aim Trials的组织主页

    290 位关注者

    Postpartum depression affects many new mothers in our community. Aim Trials is conducting research on a single-dose investigational treatment that could make a difference. If you're 18-45 years old, experiencing moderate to severe postpartum depression symptoms, and not currently nursing, you may qualify. Please share with anyone who might benefit from this opportunity. Together, we can support maternal mental health through research. If you are in Dallas Fort Worth area please visit : https://lnkd.in/ghUAaz8w #WomensHealth #DFW #ClinicalResearch

  • 查看Aim Trials的组织主页

    290 位关注者

    As facilitating clinical trials becomes more and more complex, research sites are uniquely positioned to take the lead in standardization efforts. With 70% of sites reporting increased management challenges, it's crucial for sites to collaborate with sponsors and CROs in developing and implementing standards. Take patient recruitment workflows: Sites often juggle multiple sponsor-specific processes, leading to inefficiencies and increased costs. By standardizing pre-screening questionnaires and demographic capture forms across studies, sites can streamline operations while meeting different sponsor requirements. At Aim Trials’ site, we've seen how standardized pre-screening methods can reduce our administrative burden while improving our data quality. Other clinical trial sites can contribute to standardization by: - Sharing operational insights with sponsors - Participating in industry working groups - Providing feedback on protocol templates - Suggesting technology integration improvements - Documenting common protocol deviation patterns The future of clinical research depends on sites, sponsors, and CROs working together to establish practical standards. It's time for sites to aide in shaping these standards rather than simply implementing them. What standardization efforts have you seen make a difference in clinical trial execution? #ClinicalResearch #ClinicalTrials #Innovation #Healthcare

    • 该图片无替代文字
  • 查看Aim Trials的组织主页

    290 位关注者

    2024 was an outstanding year at Aim Trials. We are so proud to share how our team was committed to advancing clinical research and where we are heading in the new year. We wanted to brag a bit and share our numbers. This past year we prioritized patient care and retention, screening over 800 patients, achieving an impressive 88% enrollment rate, and maintaining a 90% patient retention rate. Individuals from seven different ethnic groups participated in our studies, reflecting our continued dedication to diversity. With 22 active trials, 87% of studies enrolling on or ahead of schedule, and 95% of monitored findings resolved on time, Aim Trials has set a standard for efficiency and reliability we aim to maintain. By keeping protocol deviations under 2% and ensuring 100% source documentation completion, we’ve reinforced our commitment to data accuracy and compliance. Our commitment to innovation is reflected in our expanded facility featuring 8 dedicated research rooms and state-of-the-art secured storage with comprehensive monitoring systems. We've modernized our operations through integrated CTMS, eRegulatory systems, and an advanced patient recruitment platform that streamlines everything from digital advertising to automated patient outreach.With our improved facility, we look forward to bringing in and completing more studies. This year at Aim we saw a 60% increase in study volume. Our enhanced technology infrastructure has allowed us to scale our impact with greater precision and efficiency. These numbers are a testament to our dedication to improving clinical trial out comes, reclaiming better health for the generations to come, and serving our Dallas-Fort Worth community. Thank you to our patients, partners, and team members for being part of our incredible2024. We’re excited about what 2025 holds and remain committed to excellence in every aspect of our work. #ClinicalResearch #Healthcare #healthcareindustry #pharma #ClinicalTrials

    • 该图片无替代文字
  • Aim Trials转发了

    查看Sameer Meharunkar的档案

    Chief Growth Officer, Aim Trials

    ?? Excited to represent Aim Trials at SCOPE Summit 2025 (Summit for Clinical Ops Executives), the premier clinical research conference celebrating its 16th year! Looking forward to engaging with Clinical Operations leaders to exchange insights on: - Operational excellence in site management - Emerging trends in clinical trial execution - Best practices in patient recruitment and retention As a specialized site in mental health and internal medicine, I'm particularly keen to connect with: - Clinical Operations Executives driving innovation - Sponsors seeking experienced sites for CNS and internal medicine trials - CROs looking to expand their site network - Digital solution providers revolutionizing trial operations ?? Rosen Shingle Creek, Orlando ?? February 3-6, 2025 Let's schedule a meeting to discuss how Aim Trials can support your clinical research initiatives! DM me to connect. Visit our website: www.aimtrials.com #SCOPE2025 #ClinicalOperations #ClinicalTrials #MentalHealth #InternalMedicine #ClinicalResearch #DigitalHealth #CRO

  • Aim Trials转发了

    Exciting to see continued investment and commitment in advancing neuropsychiatric and neurodegenerative research. This strategic move by J&J reinforces the growing importance of mental health treatment innovation. As a clinical research site focused on mental health studies, we're optimistic about the future of neuropsychiatric drug development and its potential impact on patient care. #MentalHealth #ClinicalResearch #Neuroscience #Innovation

    查看Joaquin Duato的档案
    Joaquin Duato Joaquin Duato是领英影响力人物

    Tackling the world’s toughest health challenges as Chairman and Chief Executive Officer of Johnson & Johnson

    Building on our nearly 70-year legacy in neuroscience, Johnson & Johnson today announced plans to acquire Intra-Cellular Therapies.? ? This unique opportunity to add Intra-Cellular Therapies, Inc., to our Innovative Medicine business reinforces our commitment to transforming care and advancing research in some of today’s most prevalent and debilitating neuropsychiatric and neurodegenerative disorders.? ? The massive societal impact of these conditions underscores the importance of this opportunity to use Johnson & Johnson’s world-class expertise to deliver meaningful solutions to patients across a wide range of neuropsychiatric and neurodegenerative disorders. With its differentiated, commercialized therapy and promising clinical-stage pipeline, the acquisition of Intra-Cellular Therapies serves as a strategic near- and long-term growth catalyst for Johnson & Johnson and offers compelling value to patients, health systems and shareholders.? ? We look forward to welcoming the Intra-Cellular Therapies team to Johnson & Johnson.? ? Please refer to today’s full announcement for key information and cautionary statements: https://lnkd.in/eGvnAhK6? ? Johnson & Johnson Innovative Medicine #JNJ #MyCompany?

    • 该图片无替代文字
  • Aim Trials转发了

    Thank you Nuha Omer for having me on Hidden Bias! Your thoughtful questions and genuine interest in mental health awareness and clinical research made for such an engaging conversation. It's inspiring to see how you've grown this platform from a high school project into a meaningful avenue for important discussions. Looking forward to seeing Hidden Bias continue to challenge perceptions and break down barriers in healthcare and beyond. Congratulations on reaching 20 episodes! ?? #MentalHealth #ClinicalResearch #BreakingBarriers

    查看Nuha Omer的档案

    Health Science Major and Business Minor at Rice University | Lead Podcaster at ktru

    Celebrating 20 Episodes of Hidden Bias! What began as a high school passion project has grown into something I’m incredibly proud of—a podcast that’s sparked meaningful conversations, joined a radio station, and allowed me to connect with so many amazing individuals. Today, I’m thrilled to share the 20th episode of Hidden Bias. For this milestone episode, I had the pleasure of interviewing Sonia Prashar, founder of Aim Trials, about breaking the stigma around clinical research in the mental health sector. We dove into: - How mental health is perceived within South Asian communities. - The impact of COVID-19 in opening up conversations about clinical research. - The innovative work Aim Trials is doing to promote understanding and remove fear surrounding clinical research. This episode highlights the importance of challenging biases and fostering open dialogue—principles that have guided Hidden Bias since the very beginning. Listen to the episode now: https://lnkd.in/giRT5Wrt And follow Hidden Bias on Instagram: https://lnkd.in/gnN8k7jU

  • 查看Aim Trials的组织主页

    290 位关注者

    Wishing everyone a Happy New Year 2025! A special acknowledgment to our partners in the clinical research & pharmaceutical community - your dedication to advancing healthcare continues to inspire us. A special thank you to our incredible team - our staff, investigators, and therapists. Your commitment to excellence and patient care made 2024 a remarkable year in advancing mental health, neurology, infectious disease, and women's health research. We look forward to another year of contributing to innovative clinical trials and expanding treatment options across these vital therapeutic areas. Your trust in us drives our mission to deliver quality research with compassion and integrity. Stay tuned for our 2024 Year in Review, where we'll share some exciting milestones and achievements! Sejal Mehta, MD MBA, Aditi Diggikar, Sameer Meharunkar, Sonia Prashar, Crystal Salas, Ateka Bashir, MPH, Nilam Patel #ClinicalResearch #MentalHealth #Neurology #WomensHealth #InfectiousDisease #Innovation #Healthcare #NewYear2025 #AimTrials

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字

相似主页

查看职位